These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 27737772)
1. The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Dietz AC; Duncan CN; Alter BP; Bresters D; Cowan MJ; Notarangelo L; Rosenberg PS; Shenoy S; Skinner R; Walters MC; Wagner J; Baker KS; Pulsipher MA Biol Blood Marrow Transplant; 2017 Jan; 23(1):24-29. PubMed ID: 27737772 [TBL] [Abstract][Full Text] [Related]
2. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation. Dietz AC; Mehta PA; Vlachos A; Savage SA; Bresters D; Tolar J; Boulad F; Dalle JH; Bonfim C; de la Fuente J; Duncan CN; Baker KS; Pulsipher MA; Lipton JM; Wagner JE; Alter BP Biol Blood Marrow Transplant; 2017 May; 23(5):726-735. PubMed ID: 28115275 [TBL] [Abstract][Full Text] [Related]
3. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. Dietz AC; Savage SA; Vlachos A; Mehta PA; Bresters D; Tolar J; Bonfim C; Dalle JH; de la Fuente J; Skinner R; Boulad F; Duncan CN; Baker KS; Pulsipher MA; Lipton JM; Wagner JE; Alter BP Biol Blood Marrow Transplant; 2017 Sep; 23(9):1422-1428. PubMed ID: 28533057 [TBL] [Abstract][Full Text] [Related]
4. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Shenoy S; Gaziev J; Angelucci E; King A; Bhatia M; Smith A; Bresters D; Haight AE; Duncan CN; de la Fuente J; Dietz AC; Baker KS; Pulsipher MA; Walters MC Biol Blood Marrow Transplant; 2018 Jul; 24(7):1313-1321. PubMed ID: 29653206 [TBL] [Abstract][Full Text] [Related]
5. Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Heimall J; Buckley RH; Puck J; Fleisher TA; Gennery AR; Haddad E; Neven B; Slatter M; Roderick S; Baker KS; Dietz AC; Duncan C; Griffith LM; Notarangelo L; Pulsipher MA; Cowan MJ Biol Blood Marrow Transplant; 2017 Aug; 23(8):1229-1240. PubMed ID: 28479164 [TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group. Mohamed SY; Fadhil I; Hamladji RM; Hamidieh AA; Fahmy O; Ladeb S; Alimoghaddam K; Elhaddad A; Nacer RA; Alsharif F; Rasheed W; Jahani M; Mousavi SA; Alseraihy A; Abdel-Rahman F; Al Jefri A; Hussein AA; Alabdulaaly A; Ibrahim A; Bekadja MA; Abboud M; Ahmed P; Dennison D; Bakr M; Benchekroun S; Hussain F; Othman TB; Aljurf M; Ghavamzadeh A Hematol Oncol Stem Cell Ther; 2011; 4(2):81-93. PubMed ID: 21727769 [TBL] [Abstract][Full Text] [Related]
7. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Shenoy S; Angelucci E; Arnold SD; Baker KS; Bhatia M; Bresters D; Dietz AC; De La Fuente J; Duncan C; Gaziev J; King AA; Pulsipher MA; Smith AR; Walters MC Biol Blood Marrow Transplant; 2017 Apr; 23(4):552-561. PubMed ID: 28065838 [TBL] [Abstract][Full Text] [Related]
8. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Heimall J; Puck J; Buckley R; Fleisher TA; Gennery AR; Neven B; Slatter M; Haddad E; Notarangelo LD; Baker KS; Dietz AC; Duncan C; Pulsipher MA; Cowan MJ Biol Blood Marrow Transplant; 2017 Mar; 23(3):379-387. PubMed ID: 28068510 [TBL] [Abstract][Full Text] [Related]
9. Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies. Chaudhri NA; Aljurf M; Almohareb FI; Alzahrani HA; Bashir Q; Savani B; Gupta V; Hashmi SK Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):173-177. PubMed ID: 28692818 [TBL] [Abstract][Full Text] [Related]
10. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Pulsipher MA; Skinner R; McDonald GB; Hingorani S; Armenian SH; Cooke KR; Gracia C; Petryk A; Bhatia S; Bunin N; Nieder ML; Dvorak CC; Sung L; Sanders JE; Kurtzberg J; Baker KS Biol Blood Marrow Transplant; 2012 Mar; 18(3):334-47. PubMed ID: 22248713 [TBL] [Abstract][Full Text] [Related]
11. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. Thakar MS; Broglie L; Logan B; Artz A; Bunin N; Burroughs LM; Fretham C; Jacobsohn DA; Loren AW; Kurtzberg J; Martinez CA; Mineishi S; Nelson AS; Woolfrey A; Pasquini MC; Sorror ML Blood; 2019 Feb; 133(7):754-762. PubMed ID: 30545834 [TBL] [Abstract][Full Text] [Related]
12. Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes. Klein OR; Bapty S; Lederman HM; Younger MEM; Zambidis ET; Jones RJ; Cooke KR; Symons HJ J Clin Immunol; 2021 Feb; 41(2):414-426. PubMed ID: 33159275 [TBL] [Abstract][Full Text] [Related]
13. Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders. Bhatt ST; Bednarski JJ Front Immunol; 2020; 11():1988. PubMed ID: 33013851 [TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity conditioning (RIC) in children with nonmalignant disorders (NMD) undergoing unrelated donor umbilical cord blood transplantation (UCBT). Parikh S; Szabolcs P Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S53-5. PubMed ID: 22226113 [No Abstract] [Full Text] [Related]
15. Combined umbilical cord blood and bone marrow from HLA-identical sibling donors for hematopoietic stem cell transplantation in children with hemoglobinopathies. Soni S; Boulad F; Cowan MJ; Scaradavou A; Dahake J; Edwards S; Walters MC Pediatr Blood Cancer; 2014 Sep; 61(9):1690-4. PubMed ID: 24803091 [TBL] [Abstract][Full Text] [Related]